| 117 | 0 | 49 |
| 下载次数 | 被引频次 | 阅读次数 |
目的观察补铁治疗对维持性血液透析患者贫血指标和促红细胞生成素类药物(ESAs)用量的影响。方法前瞻性入组2015年1-7月我科维持性血液透析患者169例,根据患者铁指标情况采用静脉补充铁剂或口服补充铁剂治疗,比较患者治疗前后的血红蛋白(Hb)、血清铁蛋白(SF)、转铁蛋白饱和度(TSAT)和ESAs治疗剂量。结果与治疗前相比,静脉补充铁剂治疗后患者的Hb、SF和TSAT水平均显著增加(P<0.05),ESAs使用剂量明显下降(P<0.01)。口服补充铁剂治疗后患者的Hb、SF、TSAT和ESAs使用剂量与治疗前相比,差异均不具有统计学意义(P>0.05)。结论针对铁储备明显低下的透析患者,通过静脉补充铁剂后可提高血透患者贫血指标,减少ESAs使用剂量;铁储备在理想范围的透析患者通过补充口服铁剂可稳定患者的Hb和铁指标,为患者的后续治疗提供了指导和帮助。
Abstract：AIM To investigate the influence of iron supplementation treatment for patients with maintenance hemodialysis on anemia and erythropoiesis-stimulating agents( ESAs) dosage. METHODS A total of 169 patients,who received maintenance hemodialysis in our hospital,were prospectively enrolled from January to July2015. The patients were treated with intravenous or oral iron agents according to intravenous iron or iron index. The levels of hemoglobin( Hb),serum ferritin( SF),transferrin saturation( TSAT) and the dosage of ESAs were compared before and after treatment. RESULTS Intravenous iron increased Hb,SF,and TSAT levels( P < 0. 05),and decreased ESAs dosage after treatment( P < 0. 01). There were no statistical differences of Hb,SF,TSAT and ESAs dosage in patients who received oral iron before and after treatment( P > 0. 05). CONCLUSION For dialysis patients with low iron reserves obviously,intravenous iron supplementation can improve anemia index,and reduce the dosage of ESAs. Oral iron can maintain the Hb and iron indicators for dialysis patients with ideal iron reserves.Iron treatment provides guidance and help for dialysis patients with subsequent treatment.
[1]Zhang LX,Wang F,Wang L,et al.Prevalence of chronic kidney disease in China:a cross-sectional survey[J].Lancet,2012,379(9818):815.
[2]Martin KJ,Gonzalez EA.Metabolic bone disease in chronic kidney disease[J].J Am Soc Nephrol,2007,18(3):875.
[3]Adeera L,Christopher R,Thompson JE,et al.Left ventricular mass index increase in early renal disease:impact of decline in hemoglobin[J].Am J Kidney Dis,1999,34(1):125.
[4]Singh AK.Should we keep hemoglobin levels as a viable outcome measure?[J].Nephrol News Issues,2010,24(3):15.
[5]Regidor D,Mcclellan MW,Kewalramani R,et al.Changes in erythropoiesis-stimulating agent(ESA)dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005and 2009[J].Nephrol Dial Transplant,2011,26(5):1583.
[6]Johnson DW,Pollock CA,Macdougall IC.Erythropoiesis-stimulating agent hyporesponsiveness[J].Nephrology(Carlton),2007,12(4):321.
[7]Besarab A,Coyne DW.Iron supplementation to treat anemia in patients with chronic kidney disease[J].Nat Rev Nephrol,2010,6(12):699.
[8]Walter H.Iron therapy for renal anemia:how much needed,how much harmful?[J].Pediatric Nephrology,2007,22(4):480.
[9]Kliger AS,Foley RN,Goldfarb DS,et al.KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD[J].Am J Kidney Dis,2013,62(5):849.
[10]Auerbach M,Ballard H.Clinical use of intravenous iron:administration,efficacy,and safety[J].Hematology Am Soc Hematol Educ Program,2010,2010:338.
[11]Besarab AH,Walter H,Silverberg D.Iron metabolism,iron deficiency,thrombocytosis,and the cardiorenal anemia syndrome[J].Oncologist,2009,14(Suppl 1):22.
[12]中国医师协会肾内科医师分会肾性贫血诊断和治疗共识专家组.肾性贫血诊断与治疗中国专家共识(2014修订版)[J].中华肾脏病杂志,2014,30(9):712.
[13]Tsubakihara Y,Nishi S,Akiba T,et al.2008 Japanese Society for Dialysis Therapy:guidelines for renal anemia in chronic kidney disease[J].Ther Aphere Dialy,2010,14(3):240.
[14]Soichiro I,Shotaro N,Yumi N,et al.Anemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan:the CKD-ROUTE study[J].Nephrology(Carlton),2015,20(9):601.
[15]Pisoni RL,Bragg-Gresham JL,Young EW,et al.Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study(DOPPS)[J].Am J Kidney Dis,2004,44(1):94.
[16]Hung SC,Kuo KL,Tarng DC,et al.Anemia management in patients with chronic kidney disease:Taiwan practice guidelines[J].Nephrology(Carlton),2014,19(12):735.
[17]Macdougall IC.Iron supplementation in the non-dialysis chronic kidney disease(ND-CKD)patient:oral or intravenous?[J].Curr Med Res Opin,2010,26(2):473.
基本信息:
DOI：10.19577/j.cnki.issn10074406.2016.04.003
中图分类号:R692;R556
引用信息:
[1]陈兰,凌毅生,林春华,等.补铁治疗对维持性血液透析患者贫血指标和促红细胞生成素类药物用量的影响[J].中国临床药学杂志,2016,25(04):210-213.DOI:10.19577/j.cnki.issn10074406.2016.04.003.
基金信息:
福建省科技厅卫生联合基金(编号2015J01524)
2016-07-25
2016-07-25